Serum omentin-1 levels as a possible risk factor of mortality in patients with diabetes on haemodialysis Marija Kocijancic a, * , Bozidar Vujicic b , Sanjin Racki b , Zlatko Cubranic c , Luka Zaputovic c , Steﬁca Dvornik d a Medical Biochemistry Laboratory of Primorsko-Goranska County Health Care-Rijeka, Kresimirova 52, 51000 Rijeka, Croatia b Department of Nephrology and Dialysis, Clinical Hospital Centre Rijeka, T. Strizica 3, 51000 Rijeka, Croatia c Department of Cardiovascular Disease, Clinical Hospital Center Rijeka, T. Strizica 3, 51000 Rijeka, Croatia d Clinical Department of Laboratory Medicine, Clinical Hospital Centre Rijeka, T. Strizica 3, 51000 Rijeka, Croatia d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e x x x ( 2 0 1 5 ) x x x – x x x a r t i c l e i n f o Article history: Received 6 November 2014 Received in revised form 18 June 2015 Accepted 28 June 2015 Available online xxx Keywords: Dialysis Diabetes mellitus Omentin-1 protein a b s t r a c t Aim: The main cause of mortality in haemodialysis (HD) patients is cardiovascular disease. Serum omentin-1 level was found to be associated with cardio-metabolic disorders. The aim of this study was to examine the role of omentin-1 as a predictor of mortality in a group of diabetes positive HD patients. Methods: A total of 120 prevalent HD patients were included in the study from December 2012 to May 2014. Patients were divided into two groups according to the presence or absence of diabetes. Venous blood samples were taken at months 0 and 18 following an overnight fast (prior to a midweek HD session). Serum omentin-1 level was assessed by enzyme-linked immunosorbent assay. Results: A total of 84 HD patients were analysed at the end of an 18-month follow-up. Omentin-1 levels of HD patients with diabetes were found to be lower than of HD patients without diabetes (9.1  5.8 ng/mL vs. 11.4  4.1 ng/mL, respectively; P = 0.015) at the end of follow-up. Omentin-1 levels of survived patients with diabetes were found to be higher than of nonsurvived patients with diabetes (16.5  10.1 ng/mL vs. 12.9  5.3 ng/mL, respectively; P = 0.045). During follow-up, 36 patients (30%) died, of whom 25 had diabetes (34%). Conclusions: Serum omentin-1 levels were signiﬁcantly lower in HD patients with diabetes. A decrease in omentin-1 levels could be an independent mortality risk factor in this patient group. Further investigation in a greater number of patients is needed. # 2015 Elsevier Ireland Ltd. All rights reserved. * Corresponding author. Tel.: +385 918999980; fax: +385 52556382. E-mail addresses: marija.percan@gmail.com (M. Kocijancic), vujicic.bozidar@gmail.com (B. Vujicic), sanjin.racki@me.com (S. Racki), zcubrani@gmail.com (Z. Cubranic), luka.zaputovic@medri.uniri.hr (L. Zaputovic), steﬁca.dvornik@medri.uniri.hr (S. Dvornik). DIAB-6448; No. of Pages 7 Please cite this article in press as: Kocijancic M, et al. Serum omentin-1 levels as a possible risk factor of mortality in patients with diabetes on haemodialysis. Diabetes Res Clin Pract (2015), http://dx.doi.org/10.1016/j.diabres.2015.06.008 Contents available at ScienceDirect Diabetes Research and Clinical Practice journal homepage: www.elsevier.com/locate/diabres http://dx.doi.org/10.1016/j.diabres.2015.06.008 0168-8227/# 2015 Elsevier Ireland Ltd. All rights reserved.